Comparative Claims At RSNA Trade Show Draw FDA Ire For Bracco Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Bracco Diagnostics says it has resolved promotional violations raised in an untitled FDA letter stating that the firm made comparative claims for its MultiHance MRI contrast imaging agent, an investigational new drug, during a November 2000 trade show in Chicago.